This guideline includes statements and recommendations based on available, high level evidence about the use of endocrine therapy for pre-menopausal and post-menopausal women with hormone receptor-positive advanced breast cancer. The guideline aims to provide health professionals with information to assist in making management recommendations for improved patient outcomes. National Breast and Ovarian Cancer Centre (NBOCC)* also develops information specifically for consumers about advanced breast cancer diagnosis and treatment options.
For information on the Pharmaceutical Benefits Scheme (PBS) listing for drugs mentioned in the guideline please refer to the PBS section of this quideline.
A clinical practice guideline developed by National Breast And Ovarian Cancer Centre (NBOCC)*
This document supplements guideline recommendations 22, 24a and 24b about the use of endocrine therapy in National Breast Cancer Centre* Clinical practice guidelines for the management of advanced breast cancer, 2nd edition, 2001 (page 9).
Incorporates published evidence to July 2007
- The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
- The Royal Australasian College of Physicians
- The Royal Australasian College of Surgeons
ISBN Print: 978-1-74127-089-1
ISBN Online: 978-1-74127-094-5
© Cancer Australia 2011
* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
|Guideline Topic||Advanced Breast Cancer|
|Cancer Types||Breast cancer|
This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.